Alternate Name(s):
Rifadin, Rifampin injection (Special Access Program)
Classification:
Rifamycin Antibiotic, Antituberculous Agent
Original Date:
June 1996
Revised Date:
May 2010
Indications:
- Straphylococcal infections resistant to first line antibiotics normally proven effective. To prevent the emergence of resistant bacteria, rifampin must always be combined with other antibiotics
Administration:
- IV intermittent infusion: over 1 hour
- PO
Dosage:
- 10-20 mg/kg/day IV/PO once daily or divided Q12H
Side Effects:
- Dermatologic: occasional flushing
- GI: vomiting, diarrhea
-
Hematologic: thrombocytopenia, leukopenia, hemolytic anemia, decreased hemoglobin
- Hepatic: transient abnormalities in LFTs
- Other: may cause red discolouration e.g., urine, sputum
- Renal: elevations in urea and serum uric acid
Parameters to Monitor:
- CBC, platelet count
- LFTs during prolonged therapy
Reconstitution and Stability:
IV Intermittent infusion:
- Rifampin 600 mg (Emergency release)
- Reconstitute with 10 mL of SWFI (60 mg/mL). Take 1 mL (60 mg) and add to 9 mL D5W (vial)
-
Final concentration: 6 mg/mL
- Stable for 4 hours
Compatibility:
- Solutions Compatible: dextrose, 0.9% NaCl
- Y-site Compatible: gentamicin
Incompatible: sodium bicarbonate, TPN
References:
- Lau E. (Editor). Drug Handbook and Formulary - The Hospital for Sick Children. Toronto; 2009-2010
- Taketomo CK, Hodding JH, Kraus DM. Pediatric Dosage Handbook 16th Edition. Hudson: Lexi-Comp Inc.; 2009